NASDAQ$THRD
Third Harmonic Bio Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Announced first quarter 2023 financial results.
Third Harmonic Bio reported a net loss of $9.1 million for the first quarter ended March 31, 2023. The company's cash and cash equivalents totaled $282.2 million as of March 31, 2023, which is expected to fund operations for at least the next twelve months.
- Progress on next generation oral KIT inhibitor program with a new development candidate planned for announcement this year.
- Preclinical mechanistic studies have provided insights into the transaminitis observed with THB001, which are being applied to the next-generation program.
- Intends to present the full data set from the discontinued Phase 1b chronic inducible urticaria study for THB001 at an upcoming scientific conference.
- Cash and cash equivalents totaled $282.2 million as of March 31, 2023.
Headline financials
Revenue & EPS history
Third Harmonic · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports
+1.0%
Avg return
Earnings day
+14.2%
Avg return
5 days after
+13.0%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+13.0%
Q3 2024
Best reaction
-11.1%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +0.6% | -0.2% | +5.8% | |
| Q4 2024 | -1.1% | +42.1% | +41.9% | |
| Q3 2024 | +13.0% | +13.0% | -11.2% | |
| Q2 2024 | +10.6% | +11.5% | +9.2% | |
| Q1 2024 | +10.2% | +11.8% | +3.3% | |
| Q4 2023 | +8.0% | +7.1% | +29.2% | |
| Q3 2023 | +0.8% | — | — | |
| Q2 2023 | -6.4% | — | — | |
| Q1 2023 | -11.1% | — | — | |
| Q4 2022 | -3.5% | — | — | |
| Q3 2021 | -1.2% | — | — | |
| Q4 2021 | -1.2% | — | — | |
| Q3 2022 | -1.2% | — | — | |
| Q1 2022 | -1.2% | — | — | |
| Q2 2022 | -1.2% | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro